At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 88 enrolled
Drug / intervention
CD 2027 +1 moredrug
Likely dose
CD 2027 3 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Vehicle-controlled, Efficacy and Safety Study of CD2027 3µg/g Oily Spray Applied Twice Daily for 8 Weeks in Subjects With Plaque-type Psoriasis
In Brief
A Phase 2 clinical trial evaluating CD 2027 and Calcitriol Vehicle for Psoriasis. Completed, enrolled 88 participants across 6 sites in 2 countries.
Detailed Summary
This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedOct 2008
Primary CompletionJan 2009
Study CompletionMar 2009
TodayJul 2026
First PostedOct 1, 2008
Enrollment StartSep 1, 2008
Primary CompletionJan 1, 2009
Study CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 17.8 years ago
Interventions
CD 2027drug
Participants applied Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
Calcitriol Vehicledrug
Participants applied placebo matched to Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.